A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma

Completed · Phase 3

Conditions studied: Malignant Melanoma

In brief

The main purpose of this research study is to compare the safety, tolerability, and anti tumor activity of an investigational drug, ABI-007 versus Dacarbazine in patients with metastatic melanoma who have not previously received chemotherapy. ABI-007 is a new preparation of the active drug paclitaxel. It contains the same medication as the prescription chemotherapy drug Abraxane®. Abraxane® is approved by the FDA for the treatment of metastatic breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Dacarbazine is approved by the FDA for the treatment of melanoma. In this study, ABI-007 and Dacarbazine will be tested as therapy for people who have not yet had any cancer treatment for the diagnosis of metastatic melanoma.

Key facts

Study ID: NCT00864253
Run by: Celgene
People needed: 529
Starts: 2009-04-23
Expected to finish: 2014-02-12
Last updated by the study team: 2019-10-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Histologically or cytologically confirmed cutaneous malignant melanoma with evidence of metastasis (Stage IV).
No prior cytotoxic chemotherapy for metastatic malignant melanoma is permitted. Prior treatment with kinase inhibitors or cytokines is permitted.
No prior adjuvant cytotoxic chemotherapy is permitted. Prior adjuvant therapy with interferon, Granulocyte-macrophage colony-stimulating factor (GM-CSF) and/or vaccines is permitted.
Male or non-pregnant and non-lactating female, and ≥ 18 years of age. If a female patient is of child-bearing potential, as evidenced by regular menstrual periods, she must have a negative serum pregnancy test Beta human chorionic gonadotropin (ß-hCG) within 72 hours prior to first study drug administration. If sexually active, the patient must agree to utilize contraception considered adequate and appropriate by the investigator.
No other current active malignancy within the past 3 years.
Radiographically-documented measurable disease (defined by the presence of at least 1 radiographically documented measurable lesion
Patient has the following blood counts at Baseline:
Absolute neutrophil count (ANC) ≥ 1.5 x 10\^9 cells/L;
platelets ≥ 100 x 10\^9 cells/L;
Hemoglobin (Hgb) ≥ 9 g/dL.
Patient has the following blood chemistry levels at Baseline:
Aspartate aminotransferase(AST) glutamic-oxaloacetic transaminase (SGOT), alanine aminotransferase (ALT) serum glutamic pyruvic transaminase (SGPT) ≤ 2.5x upper limit of normal range (ULN); ≤ 5.0 xULN if hepatic metastases present;
total bilirubin ≤ ULN;
creatinine ≤ 1.5 mg/dL.
Lactate Dehydrogenase (LDH) ≤ 2.0 x ULNa
Expected survival of > 12 weeks.
Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
Patient or his/her legally authorized representative or guardian has been informed about the nature of the study, and has agreed to participate in the study, and signed the Informed Consent form prior to participation in any study-related activities.

You may not qualify if…

History of or current evidence of brain metastases, including leptomeningeal involvement.
Patient has pre-existing peripheral neuropathy of National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Scale of Grade ≥ 2.
Prior radiation to a target lesion is permitted only if there has been clear progression of the lesion since radiation was completed.
Patient has a clinically significant concurrent illness.
Patient is, in the investigator's opinion, unlikely to be able to complete the study through the End of Study (EOS) visit.
Patient is currently enrolled, or will enroll in a different clinical study in which investigational therapeutic procedures are performed or investigational therapies are administered while participating in this study. Marker studies or studies evaluating biological correlates are permitted.
Patient has serious medical risk factors involving any of the major organ systems such that the investigator considers it unsafe for the patient to receive an experimental research drug.

Where it is running

AZ Cancer Ctr — Scottsdale, Arizona, United States
Arizona Cancer Center — Tucson, Arizona, United States
Genesis Cancer Ctr - Hot Springs — Hot Springs, Arkansas, United States
University of Arkansa for Medical Sciences — Little Rock, Arkansas, United States
Tower Cancer Research Foundation — Beverly Hills, California, United States
San Diego Pacific Oncology and Hematology Associates — Encinitas, California, United States
Loma Linda University Cancer Center — Loma Linda, California, United States
University of Southern California/Norris Cancer Center — Los Angeles, California, United States
University of CA Los Angeles — Los Angeles, California, United States
St. Mary's Medical Center — San Francisco, California, United States
University of Colorado Cancer Center — Aurora, Colorado, United States
Baptist Cancer Institute — Jacksonville, Florida, United States
Lakeland Regional Cancer Center — Lakeland, Florida, United States
University of Miami Hospital and Clincs/SCCC — Miami, Florida, United States
Waren Billhartz Cancer Center — Maryville, Illinois, United States
Indiana University — Indianapolis, Indiana, United States
IA Blood and Cancer Care, PLC — Cedar Rapids, Iowa, United States
Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
Wayne State University — Detroit, Michigan, United States
University of Minnesota — Minneapolis, Minnesota, United States
St. John's Medical Research — Springfield, Missouri, United States
Saint Louis University — St Louis, Missouri, United States
Nevada Cancer Institute — Las Vegas, Nevada, United States
Atlantic Melanoma Center — Morristown, New Jersey, United States
University of Alabama at Birmingham — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.